References
- Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333: 1540–1545
- Pant S, Copelan E A. Hematopoietic stem cell transplantation in multiple myeloma. Biol Blood Marrow Transplant 2007; 13: 877–885
- Stiff P J. Management strategies for the hard-to-mobilize patient. Bone Marrow Transplant 1999; 23(Suppl 2)S29–S33
- Sugrue M W, Williams K, Pollock B H, Khan S, Peracha S, Wingard J R, et al. Characterization and outcome of “hard to mobilize” lymphoma patients undergoing autologous stem cell transplantation. Leuk Lymphoma 2000; 39: 509–519
- Dingli D, Nowakowski G S, Dispenzieri A, Lacy M Q, Hayman S, Litzow M R, et al. Cyclophosphamide mobilization does not improve outcome in patients receiving stem cell transplantation for multiple myeloma. Clin Lymphoma Myeloma 2006; 6: 384–388
- McKibbin T, Burzunski J, Greene R, Ochoa-Bayona J, Tsai T, Callander N, et al. Paclitaxel and filgrastim for hematopoietic progenitor cell mobilization in patients with hematologic malignancies after failure of a prior mobilization regimen. Leuk Lymphoma 2007; 48: 2360, – 2366
- Calandra G, McCarty F, McGuirk F, Barlogie B, Crocker S A, Badel K. AMD3100 plus G-CSF mobilizes the majority of non-Hodgkin's lymphoma (NHL), multiple myeloma (MM), and Hodgkin's disease (HD) patients who failed prior mobilization with other regimens. Biol Blood Marrow Transplant 2007; 13: 8